AERPIO PHARMACEUTICALS INC. news, videos and press releases
For more news please use our advanced search feature.
AERPIO PHARMACEUTICALS INC. - More news...
AERPIO PHARMACEUTICALS INC. - More news...
- Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes
- Aadi Bioscience to Present at the Jefferies Global Healthcare Conference
- Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications
- Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting
- Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference
- UPDATE -- Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update
- Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update
- Aerpio Reports Second Quarter 2021 Financial Results and Provides Business Update
- Aerpio Provides Second Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting
- Aerpio Provides Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting
- Aerpio Pharmaceuticals and Aadi Bioscience Enter into a Definitive Merger Agreement
- Quantum Leap Healthcare Collaborative Discontinues Testing of Aerpio Pharmaceutical’s Razuprotafib in I-SPY COVID Trial
- Aerpio Announces Strategic Review after Topline Results from Razuprotafib Glaucoma Phase 2 Trial
- Aerpio Announces Statistically Significant Topline Results from Razuprotafib Glaucoma Phase 2 Trial
- Aerpio Reports Third Quarter 2020 Financial Results and Provides Business Update
- Aerpio Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 10
- Aerpio Hosting Key Opinion Leader Call on New Therapeutic Agents for COVID-19
- Aerpio Announces First Patient Dosed with Razuprotafib in the Phase 2 Trial for the Prevention and Treatment of ARDS in Patients with Moderate-to-Severe COVID-19
- Aerpio Announces Enrollment Completed in the 28-Day Phase 2 Razuprotafib Glaucoma Trial
- Aerpio and Quantum Leap Announce First Patients Dosed with Razuprotafib in the I-SPY COVID Trial to Treat ARDS in Critically-ill COVID-19 Patients
- Aerpio Reports Second Quarter 2020 Financial Results and Provides Business Update
- Aerpio Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 12
- Aerpio Pharmaceuticals, Inc. Announces a Second Clinical Trial with Funding from MTEC to Evaluate Razuprotafib for the Prevention and Treatment of ARDS in Patients with Moderate to Severe COVID-19
- Aerpio Announces Initiation of 28-Day Phase 2 Razuprotafib Glaucoma Trial
- Aerpio Announces Change to Virtual Format for its 2020 Annual Meeting of Stockholders due to COVID-19
- Aerpio Hosting Key Opinion Leader Call on a Novel Mechanism for the Treatment of Glaucoma
- Aerpio Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative Announce the Selection of Razuprotafib for Evaluation in the I-SPY COVID Trial for the Treatment of Acute Respiratory Distress Syndrome in COVID-19 Patients
- Aerpio Announces Amended Licensing Deal with Gossamer Bio on its Inflammatory Bowel Disease (IBD) Product Candidate GB004 (formerly AKB-4924)
- Aerpio Reports First Quarter 2020 Financial Results and Provides Business Update
- Aerpio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
